In The News: Department of Brain Health

Alzheimer's & Dementia Weekly
October 12, 2020

To further incentivize innovative ideas and opportunities in Alzheimer's disease and related dementias research, the National Institute on Aging (NIA), part of the National Institutes of Health, in late summer 2020 funded four exploratory Alzheimer’s Disease Research Centers (ADRCs). These new centers will broaden current ADRC research initiatives with underrepresented populations such as African Americans, Native Americans, and those in rural communities, all of which have different risk factors for developing Alzheimer's and related dementias.

Yahoo!
October 6, 2020

EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that the Phase 2 AscenD-LB study in patients with mild-to-moderate dementia with Lewy bodies (DLB) met its primary endpoint of demonstrating an improvement in cognition as assessed by the Neuropsychological Test Battery (NTB). In the double-blind placebo-controlled study, patients receiving neflamapimod three times daily (TID) demonstrated significant improvement on the NTB compared to those who received either placebo or neflamapimod twice daily (BID); p=0.015, effect size (Cohen's d)=0.52. In addition, statistically significant improvements (p<0.05) or trends (p<0.1) were evident on multiple secondary clinical endpoints. The full results have been accepted as a late-breaking abstract and will be shared on November 7, 2020 during an oral presentation at the 13th Clinical Trials in Alzheimer's Disease (CTAD) meeting.

PR Newswire
October 6, 2020

EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that the Phase 2 AscenD-LB study in patients with mild-to-moderate dementia with Lewy bodies (DLB) met its primary endpoint of demonstrating an improvement in cognition as assessed by the Neuropsychological Test Battery (NTB). In the double-blind placebo-controlled study, patients receiving neflamapimod three times daily (TID) demonstrated significant improvement on the NTB compared to those who received either placebo or neflamapimod twice daily (BID); p=0.015, effect size (Cohen's d)=0.52. In addition, statistically significant improvements (p<0.05) or trends (p<0.1) were evident on multiple secondary clinical endpoints. The full results have been accepted as a late-breaking abstract and will be shared on November 7, 2020 during an oral presentation at the 13th Clinical Trials in Alzheimer's Disease (CTAD) meeting.

NASDAQ
September 15, 2020

Today's Daily Dose brings you news about Gilead's acquisition of Immunomedics, Marinus' CDKL5 deficiency disorder trial results, Seattle Genetics' oncology collaborations with Merck, 89bio's NASH trial data, and Cassava Sciences' Alzheimer's trial results.

Business Insider
September 15, 2020

Today's Daily Dose brings you news about Gilead's acquisition of Immunomedics, Marinus' CDKL5 deficiency disorder trial results, Seattle Genetics' oncology collaborations with Merck, 89bio's NASH trial data, and Cassava Sciences' Alzheimer's trial results.

EurekAlert!
September 10, 2020

To further incentivize innovative ideas and opportunities in Alzheimer's disease and related dementias research, the National Institute on Aging (NIA), part of the National Institutes of Health, has funded four exploratory Alzheimer's Disease Research Centers (ADRCs). These new centers will broaden current ADRC research initiatives with underrepresented populations such as African Americans, Native Americans, and those in rural communities -- all of which have different risk factors for developing these devastating diseases.

Las Vegas Review Journal
September 10, 2020

The Cleveland Clinic Lou Ruvo Center for Brain Health is one of four medical institutions across the country receiving new federal funding to research Alzheimer’s disease and related dementias in unde......We hope you appreciate our content. Subscribe today to continue reading this story, and all of our stories.

PR Newswire
August 20, 2020

The Alzheimer's Foundation of America (AFA) will be holding a free, virtual continuing medical education (CME) program for physicians on Thursday, September 10th from 12 pm to 2:30 pm (ET). Physicians can register by clicking here.

SpineNation
July 31, 2020

Working from home definitely has its advantages. A shorter commute, comfier couches, and each day is “bring your pet to work day.”

Business Insider
July 30, 2020

Alzheimer's disease has been an unsolved puzzle for scientists since the first patient was found over 100 years ago. Different theories like cholinergic hypothesis, amyloid cascade hypothesis, and tau protein hypothesis have made progress in research but failed to bring new therapies to patients. In recent years scientists started to focus on the brain-gut axis, with its breakthrough in the fields of Parkinson's disease, depression and autism. Data linking the microbiome to Alzheimer's disease and GV-971 targeting the brain-gut axis launched by Shanghai Green Valley Pharmaceuticals were presented at the 34th Alzheimer's Association International Conference (AAIC).

PRNewswire
July 29, 2020

Alzheimer's disease has been an unsolved puzzle for scientists since the first patient was found over 100 years ago. Different theories like cholinergic hypothesis, amyloid cascade hypothesis, and tau protein hypothesis have made progress in research but failed to bring new therapies to patients. In recent years scientists started to focus on the brain-gut axis, with its breakthrough in the fields of Parkinson's disease, depression and autism. Data linking the microbiome to Alzheimer's disease and GV-971 targeting the brain-gut axis launched by Shanghai Green Valley Pharmaceuticals were presented at the 34th Alzheimer's Association International Conference (AAIC).

Yahoo!
July 29, 2020

Alzheimer's disease has been an unsolved puzzle for scientists since the first patient was found over 100 years ago. Different theories like cholinergic hypothesis, amyloid cascade hypothesis, and tau protein hypothesis have made progress in research but failed to bring new therapies to patients. In recent years scientists started to focus on the brain-gut axis, with its breakthrough in the fields of Parkinson's disease, depression and autism.